National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 2) 2025

I, Dave McNally, delegate of the Minister for Health and Ageing, make the following Determination.

Dated  26 September 2025 

Dave McNally

Contents

1  Name...................................................1

2  Commencement............................................1

3  Authority................................................1

4  Schedules................................................1

Schedule 1—Amendments 2

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1) 2

1  Name

  This instrument is the National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 2) 2025.

2  Commencement

1.     Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note:  This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 9B(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1)

1  Paragraph 7(5)(c)

Repeal the paragraph, substitute:

(c) a person who is at least 6 months old and who:

1.        has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or
2.      has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or
3.    has another chronic illness requiring regular medical follow‑up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug‑induced immune impairment); or
4.     has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or
5.       has impaired immunity, including HIV infection; or

1.        a person who is at least 6 months old but is less than 11 years old and is receiving long‑term aspirin therapy; or
2.         a woman who is pregnant.

2  Subsection 7(8)

Omit “item 207A, 207B and 207F”, substitute “items 207A, 207B, 207F, 210B and 210C”.

3  Subsection 7(9A)

Omit “item 210A”, insert “items 210A and 210D”.

4  Part 2 of Schedule 1 (table item 205, column headed “Brand”)

Omit “Vaxigrip or”.

5  After item 210A of the table in Part 2 of Schedule 1

Insert: